Expression of Mesenchyme-Specific Gene HMGA2 in Squamous Cell Carcinomas of the Oral Cavity

Cancer Research

Volumn 64, Issue 6, 2004, Pages 2024-2029

  Miyazawa, Jun ^a   Mitoro, Akira ^c   Kawashiri, Shuichi ^b   Chada, Kiran K ^c   Imai, Kazushi ^a  

^a NIPPON DENTAL UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR;

ADULT; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOMA CELL; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIUM; FEMALE; FIBROBLAST; GENE; GENE EXPRESSION; GENE LOCATION; GINGIVA; HMGA2 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; KERATINOCYTE; LYMPH NODE METASTASIS; MALE; MESENCHYME; MESENCHYMOMA; MOUTH CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SQUAMOUS CELL CARCINOMA; STAINING; SURVIVAL TIME;

CARCINOMA, SQUAMOUS CELL; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GINGIVA; HMGA2 PROTEIN; HUMANS; KERATINOCYTES; LYMPHATIC METASTASIS; MALE; MESODERM; MIDDLE AGED; MOUTH; MOUTH NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL RATE;

EID: 1542720383     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-1855     Document Type: Article

References (49)

1. Lippman SM, Hong WK. Molecular markers of the risk of oral cavity. N Engl J Med 2001;344:1323-6.
2. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA-Cancer J Clin 2003;53:5-26.
3. Ponder BA. Cancer genetics. Nature 2001;411:336-41.
4. Hay ED. A review of epithelo-mesenchymal transformation. Acta Anat 1995;154:8-20.
5. Birchmeire C, Birchmeire W, Brand-Saberi B. Epithelial-mesenchymal transition in cancer progression. Acta Anat 1996;156:217-26.
6. Thiery JP. Epithelial-mesenchymal transitions in tumor progression. Nat Rev Cancer 2002;2:442-54.
7. Thanos D, Maniatis T. The high mobility group protein HMGI(Y) is required for NF-κB-dependent virus induction of the human IFN-β gene. Cell 1992;71:777-89.
8. Carey J. Gel retardation at low pH resolves trp repressor-DNA complexes for quantitative study. Proc Natl Acad Sci USA 1988;85:975-9.
9. Wolffe A. Architectural factors. Science (Wash. DC) 2001;204:1100-1.
10. Zhou X, Benson KF, Przybysz K, et al. Genomic structure and expression of the murine Hmgic gene. Nucleic Acids Res 1996;24:4071-7.
11. Xiang X, Benson KF, Chada K. Mini-mouse: disruption of the pygmy locus in a transgenic insertional mutant. Science (Wash. DC) 1990;247:967-9.
12. Reeves R, Beckerbauer L. HMGI/Y proteins: flexible regulators of transcription and chromatin structure. Biochim Biophys Acta 2001;1519:13-29.
13. Hess JL. Chromosomal translocation in benign tumors. The HMGI proteins. Am J Clin Pathol 1998;109:251-61.
14. Arlotta P, Tai AKF, Manfioletti G, et al. Transgenic mice expressing a truncated form of the higb mobility group I-C protein develop adiposity and an abnormally high prevalence of lipomas. J Biol Chem 2000;275:14394-400.
15. Battista S, Fidanza V, Fedele M, et al. The expression of a truncated HMGI-C gene induces gigantism associated with lipomatosis. Cancer Res 2000;59:4793-7.
16. Ashar HR, Schoenberg Fejzo M, Tkachenko A, et al. Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domain. Cell 1995;82:57-65.
17. Schoenmakers EFPM, Wanschura S, Mols R, et al. Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours Nat Genet 1995;10:436-44.
18. Rogala P, Drechsler K, Kazmierczak B, et al. Expression of HMGI-C, a member of the high mobility group protein family, in a subset of breast cancers: relationship to histologic grade. Mol Carcinog 1997;19:153-9.
19. Berlingieri MT, Manfioletti G, Santro M, et al. Inhibition of HMGI-C protein synthesis expresses retrovirally induced neoplastic transformation of rat thyroid cells. Mol Cell Biol 1995;15:1545-53.
20. Mizunuma H, Miyazawa J, Sanada K, Imai K. The LIM-only protein, LMO4, and the LIM domain-binding protein, LDB1, expression in squamous cell carcinomas of the oral cavity. Br J Cancer 2003;88:1543-8.
21. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:2002-7.
22. Hermanek P, Sobin LH, editors. International Union against Cancer. TNM classification of malignant tumors, 4th ed. Berlin: Springer-Verlag; 1987.
23. Zhou X, Benson K, Ashar H, Chada K. Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 1995;376:771-4.
24. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983;11:1475-89.
25. Lee KAW, Bindereif A, Green MR. A small scale procedure for preparation of nuclear extracts that support efficient transcription and pre-mRNA splicing. Gene (Amst.) 1988;5:22-31.
26. Brabletz T, Jung A, Reu S, et al. Variable β-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci USA 2001;98:10356-61.
27. Hiubek F, Jung A, Kotzor N, Kirchner T, Brabletz T. Expression of the invasion factor laminin 72 in colorectal carcinomas is regulated by β-catenin. Cancer Res 2001;61:8089-93.
28. Kuwano H, Saeki H, Kawaguchi H, et al. Proliferative activity of cancer cells in front and center areas of carcinoma in situ and invasive sites of esophageal squamous-cell carcinoma. Int J Cancer 1998;78:149-52.
29. Lever WF, Schaumburg-Lever G, editors. Histopathology of the skin, 7th ed. Philadelphia: Lippincott; 1990.
30. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998;392:190-3.
31. Christofori G, Semb H. The role of the cell adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci 1999;24:73-6.
32. Stockinger A, Eger A, Wolf J, Beug H, Foisner R. E-cadherin regulates cell growth by modulating proliferation-dependent β-catenin transcriptional activity. J Cell Biol 2001;154:1185-96.
33. Huntsman DG, Carneiro F, Lewis FR, et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 2001;344:1904-9.
34. Lo Muzio L, Staibano S, Pannone G, et al. β- and γ-Catenin expression in oral squamous cell carcinomas. Anticancer Res 1999;19:3817-26.
35. Wilkins BS, Harris S, Waseem NH, Lane DP, Jones DB. A study of cell proliferation in formalin-fixed, wax-embedded bone marrow trephine biopsies using the monoclonal antibody PC10, reactive with proliferating cell nuclear antigen (PCNA). J Pathol 1992;166:45-52.
36. Orimo A, Tomioka Y, Shimizu Y, et al. Cancer-associated myofibroblasts possess various factors to promote endometrial tumor progression. Clin Cancer Res 2001;7:3097-105.
37. Powell DW, Mifflin RC, Valentich JD, et al. Paracrine cells important in health and disease Am J Physiol 1999;277:C1-19.
38. Kazmierczak B, Dal Cin P, Sciot R, Van den Berghe H, Bullerdiek J. Inflammatory myofibroblastic tumor with HMGIC rearrangement. Cancer Genet Cytogenet 1999;112:156-60.
39. Hirning-Holz U, Wilda M, Rippe V, Bullerdiek J, Hameister H. The expression pattern of the Hmgic gene during development. Genes Chromosomes Cancer 1998;23:350-7.
40. Hunter T. Oncoprotein networks. Cell 1997;88:333-46.
41. Abate-Shen C. Deregulated homeobox gene expression in cancer: cause or consequence? Nat Rev Cancer 2002;2:777-85.
42. Chiappetta G, Manfioletti G, Pentimalli F, et al. High mobility group HMGI(Y) protein expression in human colorectal hyperplastic and neoplastic diseases. Int J Cancer 2001;91:147-51.
43. Weinstein RS, Merck FB, Alroy J. The structure and function of intercellular junctions in cancer. Adv Cancer Res 1976;23:23-89.
44. Gobbert HR, Wagner R, Moll R, Gerharz CD. Tumor dedifferentiation: an important step in tumor invasion. Clin Exp Metastasis 1985;3:257-79.
45. Frixen U, Behrens J, Sachs M, et al. E-cadherin mediated cell-cell adhesion prevents invasiveness of human carcinoma cell lines. J Cell Biol 1991;111:173-85.
46. Oft M, Akhurst RJ, Balmain A. Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat Cell Biol 2002;4:487-94.
47. Grille SJ, Bellacosa A, Upson J, et al. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res 2003;63:2172-8.
48. Reeves R, Edberg DD, Li Y. Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells. Mol Cell Biol 2001;21:575-94.
49. Wood LJ, Maher JF, Bunton TE, Resar LMS. The oncogenic properties of the HMG-I gene family. Cancer Res 2000;60:4256-61.